Recital 25, Regulation (EU) 2026/2348

In force

The application for the renewal of the approval of the active substance buprofezin was submitted on 29 January 2019 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 11 February 2020 that it had assessed the admissibility of the application pursuant to Article 3 of Implementing Regulation (EU) No 844/2012, and in particular its completeness and timeliness, and concluded that it was admissible. The application has been made public by the Authority. On 28 April 2022, the rapporteur Member State submitted the draft renewal assessment report to the Authority, which conducted a public consultation on it between 9 June and 8 August 2022. On 28 October 2022, the Authority requested additional information for the purposes of the renewal assessment pursuant to Article 13(3) of Implementing Regulation (EU) No 844/2012 and the applicant submitted that information on 30 November 2022 within the deadline given. On 24 July 2023, the Authority requested additional information for the purposes of assessment of the approval criteria concerning endocrine disrupting properties set out in points 3.6.5 and 3.8.2 of Annex II to Regulation (EC) No 1107/2009, as amended by Regulation (EU) 2018/605, pursuant to Article 13(3a) of Implementing Regulation (EU) No 844/2012 and the applicant submitted that information on 10 October 2023 within the deadline given. On 1 April 2025, the Authority adopted its updated conclusion and communicated it to the applicant, the Member States and the Commission. The Commission initiated preliminary discussions on the renewal of the approval of the active substance buprofezin in the Standing Committee on 14 May 2025. The draft renewal report and the draft implementing regulation were first discussed in the Standing Committee on 10 December 2025. The Standing Committee voted in favour of the Commission’s proposal for non-renewal of buprofezin on 25 September 2026. As additional time is necessary for the Commission to adopt the ensuing risk management decisions, the duration of the extension of the approval period should be set at 3 months, until 15 March 2027.